Minor-drug-resistant HIV populations and treatment failure

Future Virology

Volumn 2, Issue 3, 2007, Pages 293-302

  Gao, Feng ^a   Wang, Dongning ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Drug resistance; Fitness; HIV; Minor population; Mutation; Resistance test; Selection; Treatment failure

Indexed keywords

ABACAVIR; ATAZANAVIR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; TENOFOVIR; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; COST BENEFIT ANALYSIS; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LINKAGE ANALYSIS; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; VIRUS DETECTION; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

EID: 34249314428     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.2.3.293     Document Type: Review

References (55)

1. Hirsch MS, Brun-Vezinet F, Clotet B et al.: Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin. Infect. Dis. 37(1), 113-128 (2003).
2. Richman DD: Antiviral drug resistance. Antiviral. Res. 71(2-3), 117-121 (2006).
3. Grant RM, Hecht FM, Warmerdam M et al.: Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288(2), 181-188 (2002).
4. Little SJ, Holte S, Routy JP et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347(6), 385-394 (2002).
5. Jourdain G, Ngo-Giang-Huong N, Le Coeur S et al.: Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N. Engl. J. Med. 351(3), 229-240 (2004).
6. Grubb JR, Singhatiraj E, Mondy K, Powderly WG, Overton ET: Patterns of primary antiretroviral drug resistance in antiretroviral-naive HIV-1-infected individuals in a midwest university clinic. AIDS 20(16), 2115-2116 (2006).
7. Viani RM, Peralta L, Aldrovandi G et al.: Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study. J. Infect. Dis. 194(11), 1505-1509 (2006).
8. Metzner KJ, Rauch P, Walter H et al.: Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS 19(16), 1819-1825 (2005).
9. Johnson JA, Li JF, Morris L et al.: Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J. Infect. Dis. 192(1), 16-23 (2005).
10. Cai F, Chen H, Hicks CB, Bartlett JA, Zhu J, Gao F: Detection of minor drug-resistant populations by parallel allele-specific sequencing. Nat. Methods 4(2), 123-125 (2007).
11. Hance AJ, Lemiale V, Izopet J et al.: Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J. Virol. 75(14), 6410-6417 (2001).
12. Domingo E, Mas A, Yuste E et al.: Virus population dynamics, fitness variations and the control of viral disease: an update. Prog. Drug Res. 57, 77-115 (2001).
13. Clavel F, Hance AJ: HIV drug resistance. N. Engl. J. Med. 350(10), 1023-1035 (2004).
14. Colgrove R, Japour A: A combinatorial ledge: reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance. Antiviral Res. 41(1), 45-56 (1999).
15. Najera I, Holguin A, Quinones-Mateu ME et al.: Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J. Virol. 69(1), 23-31 (1995).
16. Jung A, Maier R, Vartanian JP et al.: Multiply infected spleen cells in HIV patients. Nature 418(6894), 144 (2002).
17. Levy DN, Aldrovandi GM, Kutsch O, Shaw GM: Dynamics of HIV-1 recombination in its natural target cells. Proc. Natl Acad. Sci. USA 101(12), 4204-4209 (2004).
18. Brenner BG, Routy JP, Petrella M et al.: Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J. Virol. 76(4), 1753-1761 (2002).
19. Daar ES, Richman DD: Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance. AIDS Res. Hum. Retroviruses 21(5), 343-357 (2005).
20. Palmer S, Kearney M, Maldarelli F et al.: Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J. Clin. Microbiol. 43(1), 406-413 (2005).
21. Svarovoskaia ES, Margot NA, Bae AS, Waters JM, Borroto-Esoda K, Miller MD: Allele-specific PCR shows low-level K65R in treatment-experienced patients with L74V in the absence of tams. Antivir. Ther. 11, S80 (2006) (Abstract No.80).
22. Charpentier C, Dwyer DE, Mammano, F, Lecossier D, Clavel F, Hance AJ: Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J. Virol. 78(8), 4234-4247 (2004).
23. Deeks SG, Wrin T, Liegler T et al.: Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344(7), 472-480 (2001).
24. Palmer S, Boltz V, Martinson N et al.: Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc. Natl. Acad. Sci. USA 103(18), 7094-7099 (2006).
25. Luber AD: Genetic barriers to resistance and impact on clinical response. MedGenMed 7(3), 69 (2005).
26. Shet A, Berry L, Mohri H et al.: Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J. Acquir. Immune Defic. Syndr. 41(4), 439-446 (2006).
27. Novak RM, Chen L, MacArthur RD et al.: Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin. Infect. Dis. 40(3), 468-474 (2005).
28. Ibe S, Hotta N, Takeo U et al.: Prevalence of drug-resistant human immunodeficiency virus type 1 in therapy-naive patients and usefulness of genotype testing. Microbiol. Immunol. 47(7), 499-505 (2003).
29. Leigh Brown AJ, Frost SD, Mathews WC et al.: Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J. Infect. Dis. 187(4), 683-686 (2003).
30. Nicastri E, Sarmati L, d'Ettorre G et al.: Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J. Med. Virol. 69(1), 1-6 (2003).
31. Wainberg MA: The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev. Anti. Infect. Ther. 2(1), 147-151 (2004)
32. Bleiber G, Munoz M, Ciuffi A, Meylan P, Telenti A: Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1. J. Virol. 75(7), 3291-3300 (2001).
33. Martinez-Picado J, DePasquale MP, Kartsonis N et al.: Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc. Natl Acad. Sci. USA 97(20), 10948-10953. (2000).
34. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R: Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439(7074), 344-348 (2006).
35. Brenner B, Routy JP, Quan Y et al.: Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 18(12), 1653-1660 (2004).
36. Ghosn J, Pellegrin I, Goujard C et al.: HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 20(2), 159-170 (2006).
37. Delaugerre C, Morand-Joubert L, Chaix ML et al.: Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antivir. Ther. 9(3), 415-421 (2004).
38. Little SJ, Frost S, Smith D, May S, Parkin N, Richman D: Transmission of HIV drug resistance and treatment response. Presented at: The 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25-28 February 2007 (Abstract 60).
39. Panidou ET, Trikalinos TA, Ioannidis JP: Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis. AIDS 18(16), 2153-2161 (2004).
40. Call SA, Saag MS, Westfall AO et al.: Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection. J. Infect. Dis. 183(3), 401-408 (2001).
41. Lockman S, Shapiro RL, Smeaton LM et al.: Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N. Engl. J. Med. 356(2), 135-147 (2007).
42. Ross L, Florance A, Wine B et al.: Factors associated with HIV-1 mutations to drug resistance in antiretroviral therapy naive HIV-infected individuals in the United States from 2000-2005 (prepare study). Presented at: The 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27-30 September 2006 (Abstract H-993).
43. Johnson JA, Li J, Wei X et al.: Baseline detection of low-frequency drug resistance-associated mutations is strongly associated with virological failure in previously antiretroviral-naive HIV-1 infected persons. Antivir. Ther. 11, S79 (2006).
44. Kapoor A, Jones M, Shafer RW, Rhee SY, Kazanjian P, Delwart EL: Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay. J. Virol. 78(13), 7112-7123 (2004).
45. Lecossier D, Shulman NS, Morand-Joubert L et al.: Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J. Acquir. Immune Defic. Syndr. 38(1), 37-42 (2005).
46. Roquebert B, Malet I, Wirden M et al.: Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors. AIDS 20(2), 287-289 (2005).
47. Coates EO Jr, Meade GM, Steenken W Jr, Wolinsky E, Brinkman GL: The clinical significance of the emergence of drug-resistant organisms during the therapy of chronic pulmonary tuberculosis with hydrazides of isonicotinic acid. N. Engl. J. Med. 248(26), 1081-1087 (1953).
48. Richman DD: Benefits and limitations of testing for resistance to HIV drugs. J. Antimicrob. Chemother. 53(4), 555-557 (2004).
49. Zolopa AR, Lazzeroni LC, Rinehart A et al.: Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study). Clin. Infect. Dis. 41(1), 92-99 (2005).
50. Weinstein MC, Goldie SJ, Losina E et al.: Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann. Intern. Med. 134(6), 440-450 (2001).
51. Deeks SG, Grant RM, Wrin T et al.: Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS 17(3), 361-370 (2003).
52. Halvas EK, Aldrovandi GM, Balfe P et al.: Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J. Clin. Microbiol. 44(7), 2612-2614 (2006).
53. van Laethem K, van Vaerenbergh K, Schmit JC et al.: Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. J. Acquir. Immune Defic. Syndr. 22(2), 107-118 (1999).
54. Metzner KJ, Bonhoeffer S, Fischer M et al.: Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J. Infect. Dis. 188(10), 1433-1443 (2003).
55. Simons JF, Egholm M, Lanza J et al.: Ultra-deep sequencing of HIV from drug resistant patients. Antivir. Ther. 10(Suppl. 1), S157 (2005).